Sign in

    Jon Miller

    Research Analyst at Evercore ISI

    Jon Miller is an Equity Research Associate at Evercore ISI specializing in Biotechnology and Large-Cap equities. He covers companies such as PMV Pharmaceuticals and JANX, along with a broader generalist portfolio totaling 17 stocks, and has issued predominantly Buy ratings. Despite a success rate of 32% and an average return per rating of -25.4% over the last year, his most profitable rating yielded a 43.3% gain on PMV Pharmaceuticals. Jon joined Evercore Group LLC in 2015 after earning his doctorate from Yale University in 2014, bringing strong academic credentials to his research focus in the biotechnology sector.

    Jon Miller's questions to Zymeworks (ZYME) leadership

    Jon Miller's questions to Zymeworks (ZYME) leadership • Q3 2024

    Question

    Jon Miller asked if the share repurchase program achieved its goals, about the potential for future business development deals, and how the company's ADC technology addresses tumors with variable antigen expression.

    Answer

    CEO Kenneth Galbraith affirmed the share repo's success and noted the company still feels undervalued. He stated that while the pipeline is wholly-owned, they expect to form partnerships to accelerate development. CSO Dr. Paul Moore explained their ADC design uses a multi-pronged approach, combining on-target effects, bystander activity, and a controlled payload release to effectively treat tumors with heterogeneous expression.

    Ask Fintool Equity Research AI